Hims & Hers Health, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.3 | $1.5 | $0.9 | $0.5 | $0.3 |
| Operating income | $0.1 | $0.1 | -$<0.1 | -$0.1 | -$0.1 |
| Net income | $0.1 | $0.1 | -$<0.1 | -$0.1 | -$0.1 |
| Cash Flow Statement | |||||
| Free cash flow | $0.1 | $0.2 | $<0.1 | -$<0.1 | -$<0.1 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| Share repurchases | $0.1 | $0.1 | $<0.1 | $0.0 | $0.0 |
Shares outstanding 233.3M · Free float 72.3%
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.
Earnings
Other Coverage
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground
June 2, 2026
Deals
Hims & Hers to Buy Eucalyptus in Global Expansion Deal